EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Rigel Pharmaceuticals's Enterprise Value is $615.4 Mil.
Rigel Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $79.3 Mil. Therefore, Rigel Pharmaceuticals's EV-to-FCF for today is 7.76.
The historical rank and industry rank for Rigel Pharmaceuticals's EV-to-FCF or its related term are showing as below:
RIGL'
s EV-to-FCF Range Over the Past 10 Years
Min: -819.47 Med: -4.05 Max: 94.42
Current: 7.76
During the past 13 years, the highest EV-to-FCF of Rigel Pharmaceuticals was 94.42. The lowest was -819.47. And the median was -4.05.
RIGL's EV-to-FCF is ranked better than 62.84% of 331
companies
in the Biotechnology industry
Industry Median: 16.48
vs RIGL: 7.76
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rigel Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Rigel Pharmaceuticals's share price for today is $38.72.
Rigel Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $18.720.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rigel Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rigel Pharmaceuticals EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Rigel Pharmaceuticals's EV-to-FCF falls into.
Rigel Pharmaceuticals's current Enterprise Value is $615.4 Mil.
Rigel Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $79.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rigel Pharmaceuticals (RIGL) has a EV-to-FCF of 7.76 as of Jul. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Rigel Pharmaceuticals and its competitors. According to the industry distribution chart, Rigel Pharmaceuticals ranks #123 out of 331 companies in the Biotechnology industry, placing it in the top 37.2%.
Is Rigel Pharmaceuticals' EV-to-FCF too high?
Rigel Pharmaceuticals' current EV-to-FCF is 7.76. The Biotechnology industry median EV-to-FCF is 16.48. Rigel Pharmaceuticals' value of 7.76 is 52.9% below this industry median. Based on the distribution chart, Rigel Pharmaceuticals ranks #123 out of 331 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rigel Pharmaceuticals has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' EV-to-FCF compare to CADL and IMMX?
According to the Biotechnology industry distribution chart, Rigel Pharmaceuticals ranks #123 out of 331 companies for EV-to-FCF. This puts Rigel Pharmaceuticals in the upper half of its industry. The industry median EV-to-FCF is 16.48. Rigel Pharmaceuticals' value of 7.76 is 52.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.48, based on 331 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rigel Pharmaceuticals's current EV-to-FCF of 7.76 is 52.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Rigel Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rigel Pharmaceuticals's current EV-to-FCF is 7.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rigel Pharmaceuticals (RIGL) is currently considered Significantly Overvalued. The stock's GF Value™ is $28.04, compared to a current price of $38.72 — trading 38.1% above its estimated fair value. The current EV-to-FCF is 7.76 and 52.9% below the Biotechnology industry median of 16.48. Rigel Pharmaceuticals' overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Rigel Pharmaceuticals (RIGL), the current EV-to-FCF is 7.76 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rigel Pharmaceuticals (RIGL) Overvalued in 2026?
Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued.
The current stock price of $38.72 is trading 38.1% above its estimated GF Value™ of $28.04.
GuruFocus considers Rigel Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for RIGL:
EV-to-FCF: 7.76
GF Value™: $28.04 vs. price of $38.72 (38.1% above fair value)
Industry Position: 52.9% below the Biotechnology median (#123 of 331)
No single metric tells the full story. See the RIGL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
76GF Score
Get the complete analysis for RIGL
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RIGL has been successfully added to your 
